Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia, Neglected Diseases Score Big In Nobel Prize Win

This article was originally published in PharmAsia News

Executive Summary

Health campaigners and organizations working in the area of drugs for neglected diseases have hailed the Nobel Prize awarded to three researchers in the field, but the move also highlights shortcomings and research gaps.

You may also be interested in...



Strong Early Promise For Takeda 'Off The Shelf' CAR-NK Therapy

Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.

 

Japan 2010s In Review: Specialize, Focus, Innovate

Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.

Japan Pharma Unconcerned About Virus Impact - For Now

Spreading China outbreak not a point of focus for companies or analysts in quarterly results briefings.

Topics

Related Companies

UsernamePublicRestriction

Register

SC088490

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel